JGJan Jd van Gool

Jan Jd van Gool

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan Jd van Gool has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Herbert Hirche

    Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen-Duisburg University, Essen, Germany

    2 shared publications
  • Hildegard Lax

    Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen-Duisburg University, Essen, Germany

    2 shared publications
  • Tom P. V. M. de Jong

    University Children’s Hospitals UMC Utrecht and AMC Amsterdam

    2 shared publications
  • Aart J. Klijn

    Department of Pediatric Urology, University Medical Center Utrecht/Wilhelmina Children’s Hospital, 3584 CX Utrecht, The Netherlands

    1 shared publication
  • An Bael

    Department of Pediatrics, University Hospital Antwerp, Antwerp, Belgium

    1 shared publication
  • Bas Shj Zegers

    Department of Pediatrics, Máxima Medical Center Veldhoven, The Netherlands and Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

    1 shared publication

Latest Publications

  • Fallacies of clinical studies on folic acid hazards in subjects with a low vitamin B12status

    by Jan D. van Gool, Herbert Hirche, Hildegard Lax, Luc De Schaepdrijver

    A 2016 plea for revision of the 1 mg/day upper level of folic acid intake prompted us to comprehensively review the 1945–2017 literature on folic acid hazards in subjects with low cyanocobalamin. The concept of folic acid treatment ‘masking’ the anemia in undiagnosed cyanocobalamin deficiency, thereby delaying the diagnosis of neuropathy, does not account for the dissociation between the deficiency’s hematologic and neurologic manifestations. Possible risks of this concept were addressed by 1963–1971 FDA rulings, classifying all folic acid preparations as prescription-only drugs, delivering ≤1 mg daily. The neuropathy in folic acid trials for ‘pernicious anemia’ is due to the singular use of folic acid–neuropathy improved or disappeared with replacement of folic acid by liver extract or cyanocobalamin. The hypothesis that cognitive impairment in ‘subclinical’ cyanocobalamin deficiency is folate-mediated is untenable. Of 6 papers specifically investigating this, none could prove that increased cognitive impairment was related to high folate intake. This review fully supports the safety of the 1 mg/day upper level for folic acid intake.


  • Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence

    by Jan D. van Gool, Tom P. V. M. de Jong, Pauline Winkler‐Seinstra, Tytti Tamminen‐Möbius, Hildegard Lax, Herbert Hirche, Rien J. M. Nijman, Kelm Hjälmås, Ulf Jodal, Hannsjörg Bachmann, et al.

    Objective Functional urinary incontinence causes considerable morbidity in 8.4% of school‐age children, mainly girls. To compare oxybutynin, placebo, and bladder training in overactive bladder (OAB), and cognitive treatment and pelvic floor training in dysfunctional voiding (DV), a multi‐center controlled trial was designed, the European Bladder Dysfunction Study. Methods Seventy girls and 27 boys with clinically diagnosed OAB and urge incontinence were randomly allocated to placebo, oxybutynin, or bladder training (branch I), and 89 girls and 16 boys with clinically diagnosed DV to either cognitive treatment or pelvic floor training (branch II). All children received standardized cognitive treatment, to which these interventions were added. The main outcome variable was daytime incontinence with/without urinary tract infections. Urodynamic studies were performed before and after treatment. Results In branch I, the 15% full response evolved to cure rates of 39% for placebo, 43% for oxybutynin, and 44% for bladder training. In branch II, the 25% full response evolved to cure rates of 52% for controls and 49% for pelvic floor training. Before treatment, detrusor overactivity (OAB) or pelvic floor overactivity (DV) did not correlate with the clinical diagnosis. After treatment these urodynamic patterns occurred de novo in at least 20%. Conclusion The mismatch between urodynamic patterns and clinical symptoms explains why cognitive treatment was the key to success, not the added interventions. Unpredictable changes in urodynamic patterns over time, the response to cognitive treatment, and the gender‐specific prevalence suggest social stress might be a cause for the symptoms, mediated by corticotropin‐releasing factor signaling pathways. Neurourol. Urodynam. 33:482–487, 2014.


  • Open Access

    Home screening for bacteriuria in children with spina bifida and clean intermittent catheterization

    by Bas Shj Zegers, Cuno Cspm Uiterwaal, Carla C Verpoorten, Myleen Mh Christiaens, Jan Jll Kimpen, Catharine Cce de Jong-De Vos van Steenwijk, Jan Jd van Gool

    Significant bacteriuria (SBU) and urinary tract infections (UTIs) are common in patients with spina bifida and neuropathic detrusor sphincter dysfunction. Laboratory agar plated culture is the gold standard to establish SBU. It has the disadvantage of diagnostic and subsequent therapeutic delay. Leukocyte esterase tests (LETs) and dip slides proved to be useful in the general populations to exclude SBU and UTI. The aim of this study was to evaluate the reliability of LET and dip slide in children with spina bifida without symptoms of UTI. The reliability in children with asymptomatic SBU was not studied before.


  • Detrusor overactivity in spina bifida: How long does it need to be treated?

    by Elisabeth AB, Pieter Dik, Aart J. Klijn, Jan D. van Gool, Tom P.V.M. de Jong

    Aims To determine whether a lasting therapeutic effect can be expected from long‐term antimuscarinic therapy for neurogenic detrusor overactivity in spina bifida and to answer the question whether detrusor overactivity in spina bifida children with detrusor/sphincter dyssynergia is primarily based on the neuropathy or, in part, can be a secondary detrusor reaction to the functional urethral obstruction. Methods Fifteen spina bifida patients, aged between 1 and 12 years, all on a regime of clean intermittent catheterisation (CIC) and oxybutynin since shortly after birth, underwent three consecutive urodynamic studies (UDS). One prestudy UDS for treatment control, one UDS after withdrawal of oxybutynin for 3–5 days and one UDS after reinstallment of oxybutynin treatment. Urodynamic results were compared concerning detrusor overactivity, cystometric bladder capacity, and compliance. Results Detrusor overactivity was seen in two patients on the prestudy UDS. After several days of withdrawal of oxybutynin overactivity was seen in 11 patients. After oxybutynin withdrawal, bladder compliance was within safe margins for two patients only, after reinstallment, safe vesical pressures were seen in 11 patients. Conclusion The functional obstruction due to detrusor/sphincter dyssynergia has been by‐passed chronically in all these children by CIC and oxybutynin. Due to the fact that detrusor overactivity recurs immediately after withdrawal of medication after long‐term treatment with oxybutynin, one can conclude that there is no long‐lasting therapeutic effect of pharmacological suppression. This suggests that in children with detrusor/sphincter dyssynergia, detrusor overactivity is primarily of neuropathic origin.